Related Experiment Video
Updated: Mar 15, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating cell-derived microparticles as biomarkers in cardiovascular disease
Åsa Thulin1, Christina Christersson2, Jenny Alfredsson1
1Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden.
Insights
Cell-derived microparticles (MPs) show promise as biomarkers for cardiovascular diseases (CVDs). Standardized techniques are crucial for using these microparticles in clinical risk prediction and treatment monitoring.
Area of Science:
- Biomarkers
- Cardiovascular Diseases
- Cell Biology
Background:
- Cardiovascular diseases (CVDs) are a leading cause of mortality.
- Elevated cell-derived microparticles (MPs) are observed in CVD patients and those with risk factors.
- Microparticles are being investigated as potential biomarkers for risk stratification and treatment monitoring.
Purpose of the Study:
- To review the methodological challenges and progress in microparticle analysis.
- To identify promising microparticle subpopulations for clinical evaluation in CVD.
- To highlight the need for standardized techniques and large prospective studies.
Main Methods:
- Literature review of microparticle research in cardiovascular diseases.
- Discussion of technical difficulties and advancements in MP detection and quantification.
- Analysis of existing data on MP subpopulations and their clinical relevance.
Main Results:
- Subpopulations of microparticles hold potential as predictive biomarkers for CVD.
- Standardization of sensitive techniques is essential for clinical application of MP analysis.
- Further large-scale prospective studies are required to validate prognostic value.
Conclusions:
- Microparticles represent a promising area for CVD biomarker development.
- Overcoming technical hurdles is key to translating MP research into clinical practice.
- Targeted evaluation of specific MP populations is needed for improved patient risk stratification.
Abstract:
Cardiovascular diseases (CVDs) are a common cause of death, and a search for biomarkers for risk stratification is warranted. Elevated levels of cell-derived microparticles (MPs) are found in patients with CVD and in groups with risk factors for CVD. Subpopulations of MPs are promising biomarkers for improving risk prediction, as well as monitoring treatment. However, the field has been hampered by technical difficulties, and the ongoing development of sensitive standardized techniques is crucial for implementing MP analyses in the clinic. Large prospective studies are required to establish which MPs are of prognostic value in different patient groups. In this review, we discuss methodological challenges and progress in the field, as well as MP populations that are of interest for further clinical evaluation.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...